Biocryst Pharmaceuticals (BCRX) EBIT Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn | 32.30% |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn | -520.13% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 8.32% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 19.82% |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | 145.20% |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn | 10.14% |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn | 1,528.74% |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | -563.67% |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | 230.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 230.57% |
| Mar 31, 2026 | -3,405.22% |
| Dec 31, 2025 | 5,876.06% |
| Sep 30, 2025 | 284.70% |
| Jun 30, 2025 | 239.98% |
| Mar 31, 2025 | 246.51% |
| Dec 31, 2024 | 89.44% |
| Sep 30, 2024 | 164.52% |
| Jun 30, 2024 | 142.32% |
| Mar 31, 2024 | 49.01% |
| Dec 31, 2023 | 7.86% |
| Sep 30, 2023 | 31.67% |
| Jun 30, 2023 | 40.37% |
| Mar 31, 2023 | 43.12% |
| Dec 31, 2022 | 11.24% |
| Sep 30, 2022 | 60.87% |
| Jun 30, 2022 | -17.38% |
| Mar 31, 2022 | 2.76% |
| Dec 31, 2021 | 0.44% |
| Sep 30, 2021 | -4.01% |